Suggested remit: To appraise the clinical and cost effectiveness of cabozantinib within its marketing authorisation for previously treated radioiodine-refractory differentiated thyroid cancer.
Status In progress
Technology type Medicine
Decision Selected
Process STA pre-2018
ID number 4046

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
08 April 2022 - 11 May 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
28 January 2022 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual